|
 Mylan said on Monday that the settlement would allow it to launch
Sildenafil Citrate by December 2017, or sooner under certain
conditions, subject to approval by the U.S. Food and Drug
Administration.
Pfizer's patent for Viagra, used to treat erectile dysfunction,
expires in 2020.
Mylan did not disclose other terms of the settlement, citing
confidentiality, and added that the settlement and license agreement
was subject to review by the U.S. Department of Justice and the
Federal Trade Commission.
Mylan said Viagra had U.S. sales of about $1.3 billion last year
according to IMS Health.
Mylan's Sildenafil Citrate is currently sold in 11 European
countries.
Pfizer's shares closed down marginally at $35.09, after touching an
11-year high on Monday. Mylan's shares closed down 2.4 percent at
$68.56.
[to top of second column] |
(Reporting by Anjali Rao Koppala in Bengaluru; Editing by Savio
D'Souza)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
